Tyrosine kinase inhibitors (TKIs) targeting specific driver mutations, including EGFR, ALK, and ROS‐1, are widely used for patients with advanced NSCLC harboring corresponding driver mutations, with manageable toxicities and promising treatment efficacies.24 The gene discussed is ROS1; the disease is non-small cell lung carcinoma.